Adjuvant Pembrolizumab in Kidney Cancer from Keynote 564 OncBrothers: Practice-Changing Cancer Discussions 1:00 6 months ago 277 Скачать Далее
Adjuvant pembrolizumab improves RCC disease-free survival | Toni Choueiri Medicine Matters oncology 3:03 3 years ago 1 263 Скачать Далее
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with... ecancer 5:33 3 years ago 378 Скачать Далее
#adjuvant #pembrolizumab for #RCC #kidneycancer #cancertreatment #cancer GU Oncology Now 0:41 5 months ago 77 Скачать Далее
A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma Targeted Oncology 3:01 6 years ago 554 Скачать Далее
How Does KEYNOTE-564 Open the Door For New Adjuvant Approaches? GU Oncology Now 5:51 5 months ago 64 Скачать Далее
ASCO GU23 Toni Choueiri, MD: KEYNOTE-564 subgroup analysis | Dana-Farber Cancer Institute Dana-Farber Cancer Institute 1:01 1 year ago 172 Скачать Далее
Adjuvant Pembrolizumab vs Placebo for DFS Benefit in RCC PracticeUpdate 2:53 2 years ago 74 Скачать Далее
KEYNOTE-564, CheckMate 9ER, and More: Where Do We Stand With Advanced and Metastatic RCC? GU Oncology Now 8:33 6 months ago 226 Скачать Далее
Pembrolizumab as Adjuvant Therapy for Patients With Renal Cell Carcinoma PracticeUpdate 6:41 2 years ago 402 Скачать Далее
Updated results from the 30-month follow-up of KEYNOTE-564 European Association of Urology 6:12 2 years ago 322 Скачать Далее
ASCO22: Kidney Cancer research by Toni Choueiri, MD | Dana-Farber Cancer Institute Dana-Farber Cancer Institute 1:50 2 years ago 133 Скачать Далее
